Clinical Trials Logo

Monocytic Leukemia clinical trials

View clinical trials related to Monocytic Leukemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT05871008 Recruiting - Breast Cancer Clinical Trials

Integrated Actionable Aging Assessment for Cancer Patients Pilot

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Aging is the greatest risk factor for cancer incidence and mortality. Geriatric screening is recommended to help with treatment discussions, inform intensity of treatment, and identify supportive care needs. Despite a strong evidence base, geriatric assessments are not implemented routinely in oncologic clinics. Similarly, important information on social determinants of health, mental health, and health behaviors are inconsistently assessed, and almost never in an integrated fashion. In an effort to support clinicians delivering the recommended goal-concordant care, the investigators will integrate assessment of geriatric issues, health behaviors, mental health, and social determinants of health into an efficient, actionable contextual assessment system for older cancer patients called Integrated Aging Assessment for Action for Cancer Patients (IA3-CP). The investigators will use D&I strategies including co-creation engagement approaches and form-function methods to develop workflow processes that feasibly integrate the IA3-CP into usual initial assessment with the oncology team. Our objective is to develop and conduct a randomized pilot of the IA3-CP system and hypothesize that our results will show it can be implemented consistently, acted on, improve quality of care, and enhance patient-provider interactions.

NCT ID: NCT05282459 Recruiting - Leukemia Clinical Trials

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Start date: January 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1b/2, open-label, single arm study to evaluate if enasidenib is safe and effective in improving anemia and decreasing transfusion needs in subjects diagnosed with lower risk myelodysplastic syndrome (MDS) or nonproliferative chronic myelomonocytic leukemia (CMML) without a mutation in isocitrate dehydrogenase type 2 (IDH2 wildtype). Other objectives include assessment of improvements in platelet production and characterization of the mechanism of action of enasidenib in enhancing endogenous erythropoiesis.

NCT ID: NCT04714372 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Start date: November 3, 2021
Phase: Phase 1
Study type: Interventional

This Phase I open-label dose escalation study is conducted in two stages with a primary endpoint to identify the maximum tolerated dose (MTD) of FT538 when administered with daratumumab in patients 12 years and older with advanced acute myeloid leukemia (AML) and related myeloid diseases.

NCT ID: NCT03613727 Completed - Myelodysplasia Clinical Trials

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.